Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib
It should be noted that in patients treated with ribociclib, increases in SAT volume and SAT SUV mean are independent risk factors for PFS.
Authors
- Özlem Şahin (ORCID: https://orcid.org/0000-0001-5318-0066)
- Mehmet Artaç (ORCID: https://orcid.org/0000-0003-2335-3354)
- Mustafa Erol (ORCID: https://orcid.org/0000-0003-3121-5330)
- Murat Araz (ORCID: https://orcid.org/0000-0002-4632-9501)
- Ahmet Fatih Oruç (ORCID: https://orcid.org/0009-0003-0923-5148)
- Melek Karakurt Eryılmaz (ORCID: https://orcid.org/0000-0003-2597-5931)
Institutions
- Necmettin Erbakan University (TR)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-09-13
- DOI
- https://doi.org/10.3390/curroncol32090510
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00